Regeneron Files 2025 Proxy Statement on Executive Compensation
Ticker: REGN · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 872589
| Field | Detail |
|---|---|
| Company | Regeneron Pharmaceuticals, Inc. (REGN) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
Regeneron's 2025 proxy statement is out, detailing exec pay for 2024. Vote wisely.
AI Summary
Regeneron Pharmaceuticals, Inc. filed its Definitive Proxy Statement (DEF 14A) on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity awards granted to its PEO (Principal Executive Officer) and Non-PEO NEOs (Named Executive Officers) for the fiscal year 2024. It also provides information on the company's fiscal years 2020 through 2024 for comparative purposes.
Why It Matters
This filing provides shareholders with crucial information regarding how Regeneron's top executives are compensated, impacting decisions on executive pay and corporate governance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and is not indicative of immediate financial risk.
Key Numbers
- 2024 — Fiscal Year (Primary year for executive compensation details in this filing.)
- 2020-2024 — Comparative Fiscal Years (Range of fiscal years for which data is presented for comparison.)
Key Players & Entities
- REGENERON PHARMACEUTICALS, INC. (company) — Filer of the DEF 14A
- 0000872589 (company) — Central Index Key for Regeneron Pharmaceuticals, Inc.
- 20250429 (date) — Filing date of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for which compensation details are provided
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information regarding executive compensation, board of directors, and other corporate governance matters, including details on equity awards for the fiscal year ending December 31, 2024.
When was this Definitive Proxy Statement filed?
This Definitive Proxy Statement was filed on April 29, 2025.
Which fiscal year's executive compensation is detailed in this filing?
The filing details executive compensation for the fiscal year ending December 31, 2024, with comparative data for fiscal years 2020 through 2023.
What type of compensation details are highlighted for PEO and Non-PEO NEOs?
The filing highlights equity awards, including those granted in the covered year, year-end values of outstanding and unvested awards, and changes in the fair value of prior year grants.
What is Regeneron Pharmaceuticals, Inc.'s Central Index Key (CIK)?
Regeneron Pharmaceuticals, Inc.'s Central Index Key (CIK) is 0000872589.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding REGENERON PHARMACEUTICALS, INC. (REGN).